CTA
BBIO icon

Carillon Tower Advisers’s BridgeBio Pharma BBIO Stock Holding History

Carillon Tower Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$13.5M Buy
+190,273
New +$9.18M 0.08% 302

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carillon Tower Advisers's BBIO Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in BridgeBio Pharma (BBIO) in Q4 2020: 190,273 shares worth $13.5M. The stake represents 0.08% of the portfolio and ranks #302 among its holdings.

161 funds tracked by Wall St. Rank hold BBIO as of Q4 2020.

  • Carillon Tower Advisers held 190,273 shares of BridgeBio Pharma worth $13.5M as of Q4 2020.
  • BridgeBio Pharma was a new Carillon Tower Advisers position in Q4 2020.
  • BridgeBio Pharma made up 0.08% of Carillon Tower Advisers's portfolio in Q4 2020, its #302 holding.
  • 161 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.